دورية أكاديمية
Effectiveness of NEM ® brand eggshell membrane in the treatment of suboptimal joint function in dogs: a multicenter, randomized, double-blind, placebo-controlled study.
| العنوان: | Effectiveness of NEM ® brand eggshell membrane in the treatment of suboptimal joint function in dogs: a multicenter, randomized, double-blind, placebo-controlled study. |
|---|---|
| المؤلفون: | Ruff KJ; ESM Technologies LLC, Carthage, kruff@esmingredients.com., Kopp KJ; Kopp Veterinary Consulting, St Louis., Von Behrens P; Clarkson-Wilson Veterinary Clinic, Chesterfield., Lux M; Mackenzie Pointe Animal Hospital, St Louis., Mahn M; Midwest Veterinary Referral Center, Chesterfield, MO, USA., Back M; ESM Technologies LLC, Carthage, kruff@esmingredients.com. |
| المصدر: | Veterinary medicine (Auckland, N.Z.) [Vet Med (Auckl)] 2016 Aug 18; Vol. 7, pp. 113-121. Date of Electronic Publication: 2016 Aug 18 (Print Publication: 2016). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Dovepress Country of Publication: New Zealand NLM ID: 101724251 Publication Model: eCollection Cited Medium: Internet ISSN: 2230-2034 (Electronic) Linking ISSN: 22302034 NLM ISO Abbreviation: Vet Med (Auckl) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Auckland, N.Z.] : Dovepress, [2010]- |
| مستخلص: | Introduction: Sub-optimal joint function is extremely prevalent in dogs. Therefore, a 6-week, prospective, randomized, double-blind, placebo-controlled study was conducted at eight different veterinary clinics to evaluate the efficacy, safety, and tolerability of NEM ® brand eggshell membrane (EM), a novel dietary supplement shown in other species to help maintain healthy joints and connective tissues. Subjects and Methods: Fifty-one dogs received oral EM ~13.5 mg/kg (6 mg/lb) or placebo (excipients) once daily for 6 weeks. The primary outcome measure of this study was to evaluate the change in mean joint function following 1 week and 6 weeks of supplementation as determined via the Canine Brief Pain Inventory (CBPI) questionnaire (Q#5-10) in the treatment group versus the placebo group. Secondary outcome measures were for changes in mean CBPI pain and CBPI quality of life, and mean joint pain, mobility and lameness via Veterinary Canine Scoring Assessments (VCSA). A final secondary outcome measure was for a change in serum levels of the cartilage degradation biomarker, c-terminal cross-linked telopeptide of type-II collagen (CTX-II). Results: Supplementation with EM produced a significant treatment response versus placebo at 1 week (20.5% improvement, P =0.028), but fell shy of significance at 6 weeks post-treatment (22.5% improvement) for the primary outcome measure (CBPI Function), despite a sizeable treatment effect. Similarly, there was also a significant treatment response versus placebo at 1 week for CBPI Pain (19.4% improvement, P =0.010), but fell just shy of significance at 6 weeks (22.5% improvement), again despite a sizeable treatment effect. Results were not significant versus placebo at 1 week for CBPI quality of life (14.0% improvement), but produced a significant treatment response by the end of the 6-week study (26.8% improvement, P =0.033). Additionally, EM produced a significant treatment response versus placebo at 6 weeks for VCSA pain (23.6% improvement, P =0.012), but fell shy of significance for VCSA mobility and VCSA lameness (walking & trotting). Serum CTX-II levels in EM-supplemented dogs was significantly improved versus placebo at 6 weeks (47.9% improvement, P =0.018). There were no serious adverse events reported during the study and subject dog owners reported that EM was well tolerated by their pets. Conclusion: Supplementation with EM, ~13.5 mg/kg (6 mg/lb) taken once daily, significantly reduced joint pain and improved joint function rapidly (CBPI 1 week) and demonstrated a lasting improvement in joint pain (VCSA 6 weeks) leading to an improved quality of life (CBPI 6 weeks). Moreover, a profound chondroprotective effect was demonstrated following 6 weeks of supplementation with EM (CTX-II). Competing Interests: Disclosure KJR and MB are employed by the sponsor. KJK is a paid consultant for the sponsor. The other authors report no conflicts of interest in this work. |
| References: | Am J Vet Res. 2013 Dec;74(12):1467-73. (PMID: 24274882) Vet J. 2005 Jul;170(1):113-23. (PMID: 15993795) Am J Vet Res. 2007 Jun;68(6):631-7. (PMID: 17542696) Res Vet Sci. 2014 Jun;96(3):429-35. (PMID: 24684895) Clin Interv Aging. 2009;4:235-40. (PMID: 19554094) Vet Rec. 2008 Nov 29;163(22):654-8. (PMID: 19043090) J Med Food. 2012 Apr;15(4):360-8. (PMID: 22168811) Osteoarthritis Cartilage. 2006 Jul;14(7):670-9. (PMID: 16500121) BMC Vet Res. 2012 Sep 10;8:162. (PMID: 22963751) Curr Opin Rheumatol. 2011 Sep;23(5):465-70. (PMID: 21720244) Arthritis Rheum. 2008 Jan;58(1):15-25. (PMID: 18163481) Osteoarthritis Cartilage. 2014 May;22(5):683-9. (PMID: 24576742) Vet Rec. 2003 Apr 12;152(15):457-60. (PMID: 12723628) Dev Biol. 1984 Jul;104(1):28-36. (PMID: 6203793) Biochem J. 1962 Feb;82:352-61. (PMID: 13864145) Osteoarthritis Cartilage. 2009 Mar;17(3):384-9. (PMID: 18768336) Vet J. 2007 Jul;174(1):54-61. (PMID: 16647870) Osteoarthritis Cartilage. 2010 May;18(5):605-12. (PMID: 20175979) Vet Rec. 2003 Mar 15;152(11):323-9. (PMID: 12665145) J Vet Intern Med. 2013 Jan-Feb;27(1):22-30. (PMID: 23311715) Vet Comp Orthop Traumatol. 2009;22(5):339-45. (PMID: 19750285) Vet Radiol Ultrasound. 2002 Jul-Aug;43(4):313-8. (PMID: 12174992) Clin Rheumatol. 2009 Aug;28(8):907-14. (PMID: 19340512) J Am Vet Med Assoc. 2008 Oct 15;233(8):1278-83. (PMID: 19180716) |
| فهرسة مساهمة: | Keywords: CTX-II; EM; canine; lameness; pain; stiffness |
| تواريخ الأحداث: | Date Created: 20180728 Latest Revision: 20220318 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6044796 |
| DOI: | 10.2147/VMRR.S101842 |
| PMID: | 30050844 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 2230-2034 |
|---|---|
| DOI: | 10.2147/VMRR.S101842 |